Active	Status	Sponsor type	Region	Phase	Filter
3 Active 23 Inactive 26 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
larazotide (AT1001) / 9 Meters Biopharma
NCT05022303: AT1001 for the Treatment of COVID-19 Related MIS-C	Terminated	2	12	US	Larazotide Acetate, AT1001, Placebo	Massachusetts General Hospital	Covid19, Multisystem Inflammatory Syndrome in Children	05/24	05/24
NCT05747534: AT1001 for the Treatment of Long COVID	Recruiting	2	48	US	Larazotide Acetate, AT1001, Placebo	Massachusetts General Hospital	Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19	03/25	03/26
vurolenatide (NM-002) / 9 Meters Biopharma
NCT04379856: Proof of Concept Study in Patients With Short Bowel Syndrome Updated data from trial for SBS Mar 2021 - Mar 2021: Updated data from trial for SBS Data from trial for short bowel syndrome Dec 2020 - Dec 2020: Data from trial for short bowel syndrome	Active, not recruiting	1/2	12	US	NM-002	9 Meters Biopharma, Inc.	Short Bowel Syndrome	12/20	12/20
SecreFlo (secretin) / Repligen, 9 Meters Biopharma
No trials found
teduglutide (NM-003) / 9 Meters Biopharma
No trials found
NM-102 / 9 Meters Biopharma
No trials found
NM-136 / 9 Meters Biopharma
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
larazotide (AT1001) / 9 Meters Biopharma
NCT05022303: AT1001 for the Treatment of COVID-19 Related MIS-C	Terminated	2	12	US	Larazotide Acetate, AT1001, Placebo	Massachusetts General Hospital	Covid19, Multisystem Inflammatory Syndrome in Children	05/24	05/24
NCT05747534: AT1001 for the Treatment of Long COVID	Recruiting	2	48	US	Larazotide Acetate, AT1001, Placebo	Massachusetts General Hospital	Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19	03/25	03/26
vurolenatide (NM-002) / 9 Meters Biopharma
NCT04379856: Proof of Concept Study in Patients With Short Bowel Syndrome Updated data from trial for SBS Mar 2021 - Mar 2021: Updated data from trial for SBS Data from trial for short bowel syndrome Dec 2020 - Dec 2020: Data from trial for short bowel syndrome	Active, not recruiting	1/2	12	US	NM-002	9 Meters Biopharma, Inc.	Short Bowel Syndrome	12/20	12/20
SecreFlo (secretin) / Repligen, 9 Meters Biopharma
No trials found
teduglutide (NM-003) / 9 Meters Biopharma
No trials found
NM-102 / 9 Meters Biopharma
No trials found
NM-136 / 9 Meters Biopharma
No trials found